You have 9 free searches left this month | for more free features.

Condition

Beta-Thalassemia (1)

Healthy (1)

Sickle Cell Disease (1)

Overall Status

Completed (1)

Recruiting (1)

Withdrawn (1)

Sign in for free

Phase

phase 2 (2)

phase 1 (1)

Sponsor

Vifor (International) Inc. (3)

Collaborator

Labcorp Drug Development Inc (2)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (3)

Study Type

Interventional (3)

vamifeport

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Healthy Trial in Leeds (Vamifeport Formulation 1, Vamifeport Formulation 2)

Completed

Healthy

Vamifeport Formulation 1
Vamifeport Formulation 2

Leeds, United Kingdom

Labcorp Clinical Research Unit Ltd.

Aug 16, 2022

Sickle Cell Disease Trial in Worldwide (VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg)

Recruiting

Sickle Cell Disease

VIT-2763 120 mg
+4 more

Birmingham, Alabama
+12 more

Jan 20, 2023

Beta-Thalassemia Trial in Bulgaria, Israel, United States (VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID)

Withdrawn

Beta-Thalassemia

VIT-2763 60 mg QD
+3 more

Whittier, California
+6 more

Nov 7, 2022